Kyle Dempsey
Directeur/Membre du Conseil chez OPTINOSE, INC.
Fortune : 6 089 $ au 30/04/2024
Postes actifs de Kyle Dempsey
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| OPTINOSE, INC. | Directeur/Membre du Conseil | 10/12/2021 | - |
| Independent Dir/Board Member | 10/12/2021 | - | |
| HLS THERAPEUTICS INC. | Directeur/Membre du Conseil | 29/11/2022 | - |
| Independent Dir/Board Member | 29/11/2022 | - | |
| MVM Partners LLC | Private Equity Investor | 01/09/2017 | - |
GT Medical Technologies, Inc.
 GT Medical Technologies, Inc. Medical SpecialtiesHealth Technology GT Medical Technologies, Inc. engages in the design and development of a medical device for the treatment of brain tumors. It offers GammaTile Therapy, which is a surgically targeted radiation therapy which is placed at the end if a brain excision surgery and targets residual tumor cells. The company was founded by Heyoung McBride, Peter Nakaji, Emad Youssef, and Theresa Thomas in 2017 and is headquartered in Tempe, AZ. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Kyle Dempsey
Formation de Kyle Dempsey
| Bowdoin College | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
| Harvard Business School | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 7 |
| Canada | 2 |
Opérationnelle
| Director/Board Member | 3 |
| Independent Dir/Board Member | 2 |
| Private Equity Investor | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 4 |
| Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| OPTINOSE, INC. | Health Technology |
| HLS THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
| MVM Partners LLC | Finance |
GT Medical Technologies, Inc.
GT Medical Technologies, Inc. Medical SpecialtiesHealth Technology GT Medical Technologies, Inc. engages in the design and development of a medical device for the treatment of brain tumors. It offers GammaTile Therapy, which is a surgically targeted radiation therapy which is placed at the end if a brain excision surgery and targets residual tumor cells. The company was founded by Heyoung McBride, Peter Nakaji, Emad Youssef, and Theresa Thomas in 2017 and is headquartered in Tempe, AZ. | Health Technology |
- Bourse
- Insiders
- Kyle Dempsey
- Expérience